Standard Biotools is trading 5.84% down at $0.71, after falling from the August 13 close of $0.75; no fresh company-specific announcement clearly explains the August 14 decline.
- Recent second-quarter results showed $20.1 million in revenue, while reported coverage highlighted a wider continuing-operations loss.
- Those results were released August 5 and may remain an overhang; broader markets are modestly lower without establishing a clear macro catalyst.